Jasper Therapeutics, Inc. - JSPR STOCK NEWS

Jasper Therapeutics (NASDAQ: JSPR) announced its participation in two key conferences in September 2022. The Cantor Fitzgerald Oncology Conference in New York City will feature CEO Ronald Martell on a panel discussing cell therapy challenges on September 28 at 9 AM ET. Additionally, Wendy Pang, SVP of Research, will present at the William Blair Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 29 at 5 PM ET. For more details and registration, visit their Investor Events webpage.

Jasper Therapeutics (Nasdaq: JSPR) announced that its anti-CD117 monoclonal antibody, JSP191, has received Fast Track designation from the FDA for patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant. JSP191 is currently being evaluated in four ongoing clinical studies related to Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and other conditions. The company is also on track to initiate a new study on JSP191 for second-line therapy in lower-risk MDS patients later this year.

Jasper Therapeutics (Nasdaq: JSPR) announced key developments in its clinical programs for the second quarter of 2022. The company dosed its first patient in a trial for JSP191 as a conditioning agent for Fanconi Anemia and is on track to initiate registrational studies in acute myeloid leukemia (AML) in early 2023. Financial results showed a net loss of $10.4 million, up from $8.4 million year-over-year, with cash reserves at $60.8 million, expected to last into early 2023. The firm is advancing multiple trials, highlighting the potential of JSP191 in treating hematopoietic stem cell diseases.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022. Ronald Martell, Jeet Mahal, and Wendy Pang will engage in a fireside chat at 4 PM ET, with a live webcast available on their website. The company focuses on developing innovative stem cell therapies, including JSP191, a monoclonal antibody aimed at improving hematopoietic cell transplants. Jasper plans to begin clinical studies for JSP191 in 2023, potentially transforming treatment for serious conditions like cancer.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced its participation in the William Blair 42nd Annual Growth Stock Conference in Chicago from June 6-9, 2022. CEO Ronald Martell will present on June 9 at 8:00 AM CT, followed by a breakout session at 8:40 AM CT. A live webcast of the presentation will be accessible on the company's investor webpage. Jasper Therapeutics is focused on stem cell therapies, advancing programs such as JSP191, aimed at safer hematopoietic cell transplants. For more information, visit jaspertherapeutics.com.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced that its 2022 Annual Meeting of Stockholders will take place virtually on June 23, 2022, at 10:00 a.m. PT. Stockholders as of April 26, 2022, are eligible to participate and vote. The meeting will be accessible via a live audio webcast. Proxy materials with voting instructions have been distributed, and more details can be found on Jasper Therapeutics’ website and in the definitive proxy statement filed with the SEC on April 29, 2022.

Jasper Therapeutics, Inc. (NASDAQ: JSPR) has initiated a Phase 1/2 clinical trial at Stanford University to evaluate JSP191 as a conditioning agent for patients with Fanconi Anemia requiring bone marrow transplants. This research aims to improve donor stem cell engraftment while reducing toxicity. The trial is led by Dr. Rajni Agarwal and focuses on assessing treatment-emergent adverse events among participants. JSP191, previously tested in over 100 patients, is designed to facilitate safer allogeneic transplants. Jasper also plans further clinical trials expanding JSP191's applications.

Jasper Therapeutics reported a successful FDA meeting to initiate registrational studies for JSP191, focusing on patients with MDS and AML, expected by Q1-2023. Clinical data showed JSP191 was well tolerated, with 20 out of 24 patients free from disease progression. R&D expenses rose to $8.2 million due to increased trial costs. Cash reserves stood at $70.4 million, sufficient for operations through early 2023. The company aims to advance targeted therapies for hematopoietic stem cell transplants.

Jasper Therapeutics announced plans to initiate registrational studies for JSP191, a conditioning agent for older patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) undergoing transplants. After positive feedback from the FDA, the study protocol is being finalized with no additional studies required before initiation. Recent data showed JSP191 was well tolerated in 24 older patients with successful engraftment and minimal adverse events. The company aims to launch the study early next year, enhancing treatment outcomes for this vulnerable population.